Results of A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of The Efficacy And Safety of Sirukumab, An Anti-IL-6 Cytokine Monoclonal Antibody, In Patients with Active Rheumatoid Arthritis Despite Disease-Modifying Anti-Rheumat ...
Nov 1, 2016, 00:00
10.1016/j.jval.2016.09.1074
https://www.valueinhealthjournal.com/article/S1098-3015(16)32440-8/fulltext
Title :
Results of A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of The Efficacy And Safety of Sirukumab, An Anti-IL-6 Cytokine Monoclonal Antibody, In Patients with Active Rheumatoid Arthritis Despite Disease-Modifying Anti-Rheumat ...
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)32440-8&doi=10.1016/j.jval.2016.09.1074
First page :
A531
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
1007